Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade B 12.91 4.37% 0.54
CCXI closed up 4.37 percent on Friday, September 21, 2018, on 2.96 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CCXI trend table...

Date Alert Name Type % Chg
Sep 21 MACD Bullish Centerline Cross Bullish 0.00%
Sep 21 Pocket Pivot Bullish Swing Setup 0.00%
Sep 21 Up 3 Days in a Row Strength 0.00%
Sep 21 Up 4 Days in a Row Strength 0.00%
Sep 20 20 DMA Support Bullish 4.37%
Sep 20 Crossed Above 50 DMA Bullish 4.37%
Sep 20 MACD Bullish Signal Line Cross Bullish 4.37%
Sep 20 Up 3 Days in a Row Strength 4.37%
Sep 19 50 DMA Resistance Bearish 9.13%
Sep 19 Crossed Above 20 DMA Bullish 9.13%

Older signals for CCXI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.08
52 Week Low 5.42
Average Volume 181,761
200-Day Moving Average 10.9491
50-Day Moving Average 11.8006
20-Day Moving Average 11.9153
10-Day Moving Average 11.4685
Average True Range 0.6721
ADX 16.9
+DI 32.0868
-DI 20.6136
Chandelier Exit (Long, 3 ATRs ) 11.4837
Chandelier Exit (Short, 3 ATRs ) 12.3563
Upper Bollinger Band 13.6333
Lower Bollinger Band 10.1973
Percent B (%b) 0.79
BandWidth 28.836874
MACD Line 0.0302
MACD Signal Line -0.0801
MACD Histogram 0.1103
Fundamentals Value
Market Cap 628.79 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -20.82
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.03
Resistance 3 (R3) 13.91 13.43 13.84
Resistance 2 (R2) 13.43 13.14 13.48 13.78
Resistance 1 (R1) 13.17 12.97 13.30 13.28 13.72
Pivot Point 12.68 12.68 12.75 12.74 12.68
Support 1 (S1) 12.42 12.40 12.55 12.54 12.10
Support 2 (S2) 11.94 12.22 11.99 12.04
Support 3 (S3) 11.68 11.94 11.98
Support 4 (S4) 11.79